500TiP Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

M. Weller; D.A. Berry; N. Blondin; M. Buxton; H. Colman; J.F. de Groot; M. de la Fuente; F. Ducray; B. Ellingson; G. Gordon; A.B. Lassman; E. Lee; M. Lim; I. Mellinghoff; J. Perry; E. Sulman; W-K.A. Yung; P. Wen; A. Wick; T. Cloughesy; Macarena Ines De La Fuente

doi:10.1016/j.annonc.2024.08.569

Back

500TiP Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

Journal article

Peer reviewed

500TiP Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma

M. Weller, D.A. Berry, N. Blondin, M. Buxton, H. Colman, J.F. de Groot, M. de la Fuente, F. Ducray, B. Ellingson, G. Gordon, …

Annals of oncology, Vol.35, pp.S426-S427

2024-09

DOI: https://doi.org/10.1016/j.annonc.2024.08.569

Appears in Miller School of Medicine - Latest Publications

Metrics

1 Record Views

Details

Title: 500TiP Update on GBM AGILE: A global, phase II/III adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
Creators: M. Weller - Neurology, USZ - Universitätsspital Zürich - Klinik für Neurologie, Zurich, Switzerland
D.A. Berry - Biostatistics Department, Berry Consultants, LLC, Austin, TX, USA
N. Blondin - University of New Haven
M. Buxton - Global Coalition for Adaptive Research, Larkspur, CA, USA
H. Colman - University of Utah
J.F. de Groot - Montreal Neurological Institute and Hospital
M. de la Fuente - Neurology, Sylvester Comprehensive Cancer Center - University of Miami, Miami, FL, USA
F. Ducray - Hospices Civils de Lyon
B. Ellingson - University of California, Los Angeles
G. Gordon - Global Coalition for Adaptive Research, Larkspur, CA, USA
A.B. Lassman - Columbia University Irving Medical Center
E. Lee - Dana-Farber Cancer Institute
M. Lim - Stanford University School of Medicine
I. Mellinghoff - Memorial Sloan Kettering Cancer Center
J. Perry - Sunnybrook Health Science Centre
E. Sulman - NYU Langone Health
W-K.A. Yung - The University of Texas MD Anderson Cancer Center
P. Wen - Dana-Farber Cancer Institute
A. Wick - University Hospital Heidelberg
T. Cloughesy - Department of Neurology, UCLA, Los Angeles, CA, USA
Macarena Ines De La Fuente - UMMG Department of Neurology
Publication Details: Annals of oncology, Vol.35, pp.S426-S427
Publisher: Elsevier Ltd; AMSTERDAM
Number of pages: 2
Grant note: Cure Brain Cancer FoundationNational Brain Tumor SocietyNational Foundation for Cancer ResearchAsian Fund for Cancer Research LtdGlobal Coalition for Adaptive Research, BayerKintara therapeuticsKazia therapeuticsVigeo TherapeuticsBiohaven PharmaceuticalsPolaris Pharmaceuticals
Cure Brain Cancer Foundation, National Brain Tumor Society, National Foundation for Cancer Research, Asian Fund for Cancer Research Ltd, Global Coalition for Adaptive Research, Bayer, Kintara therapeutics, Kazia therapeutics, Vigeo Therapeutics, Biohaven Pharmaceuticals, Polaris Pharmaceuticals.
Academic Unit: Miller School of Medicine; UMMG Department of Neurology; UMMG Dept of Neurology - Neuro-Oncology Div
Language: English
Resource Type: Journal article
Record Identifier: 991032860895402976